Pre-surgery treatment for advanced penile cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two drugs given before surgery for penile cancer that has spread locally. The goal is to shrink the tumor and improve the chance of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 to 75.
- You have penile cancer that is locally advanced (has spread to nearby tissues or lymph nodes) but has not spread to distant organs.
- You have not had any treatment for this cancer yet, or if you had treatment, it finished at least 12 months ago.
- You have at least one tumor that can be measured by scans.
- You are in reasonably good health (able to do light activities, ECOG 0-2).
- Your liver, kidneys, and blood counts meet minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests a combination of two new drugs—an immunotherapy and an antibody-drug conjugate—for people with advanced squamous cell carcinoma of the skin. The goal is to see if this combo can shrink tumors and slow the cancer.
Hear when a new Penile Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.